文献速递系统性红斑狼疮

抗CD19 CAR-T细胞治疗后女性SLE患者激素水平未提示卵巢储备受损信号

Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

OBJECTIVES: Women with SLE are at increased risk of infertility due to disease activity and exposure to gonadotoxic therapies.…

要点

  • 抗CD19 CAR-T治疗后12个月AMH水平稳定,无卵巢储备受损信号。
  • FSH轻度升高但无AMH下降,激素变化需谨慎解读。
  • E2、孕酮、LH和催乳素无显著纵向变化。

核心结论

  • 抗CD19 CAR-T细胞治疗包括标准淋巴细胞清除未显示卵巢储备受损信号,基于AMH和激素谱评估。

研究设计与样本

  • 在基线和治疗后12个月测量AMH、E2、孕酮、FSH、LH和催乳素,血样采集不考虑月经周期,进行配对统计分析。

主要发现

  • AMH水平稳定:1.54 ng/ml(IQR 0.64-3.15)vs 2.14 ng/ml(0.63-3.26),P=0.886。
  • E2(243 pmol/l [186-346] vs 484 pmol/l [277-829],P=0.339)和孕酮(0.90 nmol/l [0.80-0.90] vs 1.80 nmol/l [0.90-3.40],P=0.054)显示较大变异但无显著纵向变化。
  • FSH轻度升高(6.60 IU/l [4.00-7.90] vs 7.20 IU/l [4.50-9.90],P=0.033),无伴随AMH下降。
  • LH(6.10 IU/l [5.10-12.90] vs 7.00 IU/l [5.00-12.90],P=0.946)和催乳素(10.0 µg/l [8.0-10.0] vs 8.0 µg/l [5.0-9.0],P=0.123)保持稳定。

临床怎么用

  • 对于接受抗CD19 CAR-T细胞治疗的难治性SLE女性,短期随访未观察到卵巢储备受损的激素信号。
  • FSH轻度升高需结合AMH等指标综合解读,避免单独用于评估卵巢储备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Women with SLE are at increased risk of infertility due to disease activity and exposure to gonadotoxic therapies. Anti‑CD19 chimeric antigen receptor (CAR) T‑cell therapy has recently been shown to induce durable, drug‑free remission in refractory SLE; however, its effects on ovarian function remain unknown. We assessed longitudinal changes in reproductive endocrine markers to evaluate the impact of CAR T‑cell therapy on ovarian reserve and hypothalamic-pituitary-ovarian (HPO) axis function. METHODS: Women with severe, treatment‑refractory SLE receiving autologous anti‑CD19 CAR T‑cell therapy (Miltenyi Biomedicine) in conjunction with standard lymphodepletion at two tertiary care centres were studied. Anti‑Müllerian hormone (AMH), oestradiol (E2), progesterone, follicle‑stimulating hormone (FSH), luteinizing hormone (LH) and prolactin were measured at baseline and 12 months after therapy. Blood samples were obtained independent of menstrual cycle phase. Paired statistical analyses were performed. RESULTS: Thirteen women were included; median age at CAR T‑cell therapy was 27 years. AMH levels were stable (1.54 ng/ml [IQR 0.64-3.15] vs 2.14 ng/ml [0.63-3.26]; P = 0.886). E2 (243 pmol/l [186-346] vs 484 pmol/l [277-829]; P = 0.339) and progesterone (0.90 nmol/l [0.80-0.90] vs 1.80 nmol/l [0.90-3.40]; P = 0.054) showed substantial variability without significant longitudinal change. FSH increased modestly (6.60 IU/l [4.00-7.90] vs 7.20 IU/l [4.50-9.90]; P = 0.033) without a concomitant decline in AMH. LH (6.10 IU/l [5.10-12.90] vs 7.00 IU/l [5.00-12.90]; P = 0.946) and prolactin (10.0 µg/l [8.0-10.0] vs 8.0 µg/l [5.0-9.0]; P = 0.123) remained stable. CONCLUSION: Anti‑CD19 CAR T‑cell therapy, including standard lymphodepletion, showed no signal of impaired ovarian reserve, as assessed by AMH and hormone profiles. Observed hormonal changes, including FSH, should be interpreted with caution given study limitations.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pecher AC, Henes J, Henes M, et al. Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve. Rheumatology (Oxford). 2026. PMID: 42584071. doi:10.1093/rheumatology/keag413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。